Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4427)
All Articles published online
|
Publishing Process of This Article
|
Nov 21, 2021 (publication date) through Aug 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Gordon M, Lakunina S, Sinopoulou V, Akobeng A. Minimum sample size estimates for trials in inflammatory bowel disease: A systematic review of a support resource. World J Gastroenterol 2021; 27(43): 7572-7581 [PMID: 34887650 DOI: 10.3748/wjg.v27.i43.7572] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i43/7572.htm |
| Number | Citing Articles |
| 1 |
Vassiliki Sinopoulou, Morris Gordon, Vicki Gregory, Anas Saadeh, Anthony K Akobeng. Prebiotics for induction and maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2024; 2024(3) doi: 10.1002/14651858.CD015084.pub2
|
| 2 |
Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Arni Sarian, Gordon William Moran. Infliximab for maintenance of medically-induced remission in Crohn's disease. Cochrane Database of Systematic Reviews 2024; 2024(2) doi: 10.1002/14651858.CD012609.pub2
|
| 3 |
Hongsheng Yang, Zhaopeng Huang, Miao Li, Haiyan Zhang, Lingyu Fu, Xiaoling Wang, Qiaoqiao Yang, Yun He, Wenhong Wu, Taofeng Jiang, Zhimei Sun, Tao Zhang, Dongping Lai, Xixin Wu, Lishuo Shi, Qin Guo, Yanhui Wu, Jian Tang, Kang Chao, Xiang Gao. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study. eClinicalMedicine 2023; 66: 102337 doi: 10.1016/j.eclinm.2023.102337
|
| 4 |
Samuel Hui, Vassiliki Sinopoulou, Morris Gordon, Ghazaleh Aali, Anuj Krishna, Nik Sheng Ding, Ray K Boyapati. Vedolizumab for induction and maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2023; 2023(7) doi: 10.1002/14651858.CD013611.pub2
|
| 5 |
Chris Wallace, Morris Gordon, Vassiliki Sinopoulou, Berkeley N Limketkai. Vitamin D for the treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2023; 2023(10) doi: 10.1002/14651858.CD011806.pub2
|
| 6 |
James P Franciosi, Morris Gordon, Vassiliki Sinopoulou, Evan S Dellon, Sandeep K Gupta, Craig C Reed, Carolina Gutiérrez-Junquera, Rajitha D Venkatesh, Elizabeth A Erwin, Abdullah Egiz, Assem Elleithy, Edward B Mougey. Medical treatment of eosinophilic esophagitis. Cochrane Database of Systematic Reviews 2023; 2023(7) doi: 10.1002/14651858.CD004065.pub4
|
| 7 |
Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin-Biroulet. Navigating the complexities of drug development for inflammatory bowel disease. Nature Reviews Drug Discovery 2024; 23(7): 546 doi: 10.1038/s41573-024-00953-0
|
| 8 |
Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Shellie J Radford, Mohsen Eldragini, Ana-Maria Darie, Gordon William Moran. Infliximab for medical induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2023; 2023(12) doi: 10.1002/14651858.CD012623.pub2
|
| 9 |
Aamer Imdad, Natasha G Pandit, Muizz Zaman, Nathan Zev Minkoff, Emily E Tanner-Smith, Oscar G Gomez-Duarte, Sari Acra, Maribeth R Nicholson. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2023; 2023(4) doi: 10.1002/14651858.CD012774.pub3
|
| 10 |
Vassiliki Sinopoulou, Morris Gordon, Gordon William Moran, Abdullah Mohammed Abousaleh ma Egiz, Sanjana Phlananthachai, Aditi Rane, Ahmed Hussein Ali Al-Tameemi. Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review. BMJ Open Gastroenterology 2024; 11(1): e001334 doi: 10.1136/bmjgast-2023-001334
|